MDT

86.79

+0.46%↑

113.49

-1.49%↓

VEEV

171.56

-1.05%↓

HQY

81.28

-2.94%↓

PHR.US

9.16

+2.69%↑

MDT

86.79

+0.46%↑

113.49

-1.49%↓

VEEV

171.56

-1.05%↓

HQY

81.28

-2.94%↓

PHR.US

9.16

+2.69%↑

MDT

86.79

+0.46%↑

113.49

-1.49%↓

VEEV

171.56

-1.05%↓

HQY

81.28

-2.94%↓

PHR.US

9.16

+2.69%↑

MDT

86.79

+0.46%↑

113.49

-1.49%↓

VEEV

171.56

-1.05%↓

HQY

81.28

-2.94%↓

PHR.US

9.16

+2.69%↑

MDT

86.79

+0.46%↑

113.49

-1.49%↓

VEEV

171.56

-1.05%↓

HQY

81.28

-2.94%↓

PHR.US

9.16

+2.69%↑

Home・Aktien・Lisata Therapeutics

L
Lisata Therapeutics

Open

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

4.87

Max

Schlüsselkennzahlen
By Trading Economics
Einkommen	1.3M -3M
Verkäufe	100K 100K
Gewinnspanne	-2,954
Angestellte	21

Dividenden
By Dow Jones
Nächstes Ergebnis	7. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	531K 40M
Vorheriger Eröffnungskurs	5
Vorheriger Schlusskurs	5

Lisata Therapeutics Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

6. Apr. 2026, 23:17 UTC

Ergebnisse

Samsung Forecasts Record First-Quarter Operating Profit

6. Apr. 2026, 23:00 UTC

Heiße Aktien

Stocks to Watch: Health Insurers, Mawson, Owlet

6. Apr. 2026, 22:13 UTC

Wichtige Markttreiber

Health Insurance Shares Gain on 2.48% Medicare Rate Bump

6. Apr. 2026, 21:46 UTC

Akquisitionen, Fusionen, Übernahmen

BP 'Optimizes Portfolio' and Sells 13 Thorntons Stores to Giant Oil -- OPIS

6. Apr. 2026, 17:09 UTC

Wichtige Markttreiber

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

6. Apr. 2026, 16:56 UTC

Wichtige Nachrichtenereignisse

U.S. Released 1.5 Million Bbls of Crude From SPR Last Week, DOE Data Show -- OPIS

6. Apr. 2026, 14:47 UTC

Wichtige Markttreiber

Stereotaxis Shares Rise on FDA Clearance for Synchrony

7. Apr. 2026, 00:00 UTC

Wichtige Nachrichtenereignisse

Ukraine's Lesson for Trump: Military Dominance Opens Waterways -- WSJ

6. Apr. 2026, 23:58 UTC

Market Talk

Wichtige Nachrichtenereignisse

Iran War Will Keep Oil Prices High Through 2Q, Says Westpac -- Market Talk

6. Apr. 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for Iran Cease-Fire -- Market Talk

6. Apr. 2026, 23:36 UTC

Market Talk

Gold Edges Higher as Investors Focus on U.S.-Iran Conflict -- Market Talk

6. Apr. 2026, 23:15 UTC

Market Talk

RBA Won't Raise Rates as Australia's Economy Softens Fast -- Market Talk

6. Apr. 2026, 22:52 UTC

Market Talk

Global Equities Roundup: Market Talk

6. Apr. 2026, 22:52 UTC

Market Talk

Pro Medicus Unlikely to Complete New Buyback in Full -- Market Talk

6. Apr. 2026, 22:14 UTC

Market Talk

Correction to Live Cattle Futures Article

6. Apr. 2026, 20:56 UTC

Market Talk

Mexican Private Consumption Fell in January -- Market Talk

6. Apr. 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

6. Apr. 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6. Apr. 2026, 19:58 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6. Apr. 2026, 19:58 UTC

Market Talk

Live Cattle Futures Hit Record High, Hogs Edge Up -- Market Talk

6. Apr. 2026, 19:11 UTC

Market Talk

U.S. Natural Gas Edges Up in Rangebound Trade -- Market Talk

6. Apr. 2026, 19:06 UTC

Market Talk

Treasury Yields Decline as a Belligerent Trump Talks to Reporters -- Market Talk

6. Apr. 2026, 19:03 UTC

Market Talk

Global Energy Roundup: Market Talk

6. Apr. 2026, 19:03 UTC

Market Talk

Crude Futures Edge Up As Trump's Iran Deadline Nears -- Market Talk

6. Apr. 2026, 18:36 UTC

Akquisitionen, Fusionen, Übernahmen

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6. Apr. 2026, 17:59 UTC

Market Talk

Wichtige Nachrichtenereignisse

Travel Booking Companies Facing More Demand Uncertainty Than Expected -- Market Talk

6. Apr. 2026, 17:13 UTC

Akquisitionen, Fusionen, Übernahmen

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6. Apr. 2026, 16:33 UTC

Market Talk

Oil Futures Steady as Market Awaits Trump -- Market Talk

6. Apr. 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6. Apr. 2026, 14:59 UTC

Ergebnisse

Strategy Records a $14.5 Billion Unrealized Loss in First Quarter -- WSJ

Peer-Vergleich

Kursveränderung

Lisata Therapeutics Prognose

Rating-Konsens

By TipRanks

Neutral

1 ratings

Buy

Halten

Sell

Basierend auf 1 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Lisata Therapeutics – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Gewinn vor Steuern

Verkäufe

Betriebsergebnis

Über Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.